Target family: Adrenoceptors (type: gpcr)
Target: &alpha;<sub>1D</sub>-adrenoceptor

Ligand: 5-methylurapidil (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: 5-methylurapidil (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
Published in: Mol Pharmacol

Ligand: 5-methylurapidil (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
Published in: Jpn J Pharmacol

Ligand: 5-methylurapidil (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification.
Published in: Br J Pharmacol

Ligand: 6-fluoro-noradrenaline (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6 pKi
Reference (Journal): Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes.
Published in: Mol Pharmacol

Ligand: A-119637 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9.6 pKi
Reference (Journal): Two novel and potent 3-[(o-methoxyphenyl)piperazinylethyl]-5-phenylthien.
Published in: Bioorg Med Chem Lett

Ligand: A-119637 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9.7 pKi
Reference (Journal): Two novel and potent 3-[(o-methoxyphenyl)piperazinylethyl]-5-phenylthien.
Published in: Bioorg Med Chem Lett

Ligand: A-123189 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9.5 pKi
Reference (Journal): Two novel and potent 3-[(o-methoxyphenyl)piperazinylethyl]-5-phenylthien.
Published in: Bioorg Med Chem Lett

Ligand: A-123189 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9.8 pKi
Reference (Journal): Two novel and potent 3-[(o-methoxyphenyl)piperazinylethyl]-5-phenylthien.
Published in: Bioorg Med Chem Lett

Ligand: (+)-adrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6 pKi
Reference (Journal): KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
Published in: Mol Pharmacol

Ligand: (-)-adrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (no history prior to 1951)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Selectivity of the imidazoline alpha-adrenoceptor agonists (oxymetazoline and cirazoline) for human cloned alpha 1-adrenoceptor subtypes.
Published in: Br J Pharmacol

Ligand: (-)-adrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (no history prior to 1951)
Primary target: no
Median affinity:  pEC50
Reference (Journal): The selectivity of &#x3b1;-adrenoceptor agonists for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: (-)-adrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (no history prior to 1951)
Median affinity: 6.3 pKi
Reference (Journal): Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes.
Published in: Mol Pharmacol

Ligand: (-)-adrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (no history prior to 1951)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of &#x3b1;-adrenoceptor agonists for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: (-)-adrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (no history prior to 1951)
Primary target: yes
Median affinity:  pKi
Reference (Journal): KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
Published in: Mol Pharmacol

Ligand: alfuzosin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (2003)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: alfuzosin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (2003)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Adrenoceptor subclassification: an approach to improved cardiovascular therapeutics.
Published in: Pharm Acta Helv

Ligand: amidephrine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 4.2 pKi
Reference (Journal): Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes.
Published in: Mol Pharmacol

Ligand: BMY-7378 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: BMY-7378 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
Published in: Jpn J Pharmacol

Ligand: BMY-7378 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9 pKi
Reference (Journal): Two novel and potent 3-[(o-methoxyphenyl)piperazinylethyl]-5-phenylthien.
Published in: Bioorg Med Chem Lett

Ligand: BMY-7378 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Two novel and potent 3-[(o-methoxyphenyl)piperazinylethyl]-5-phenylthien.
Published in: Bioorg Med Chem Lett

Ligand: cirazoline (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.9 pKi
Reference (Journal): Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes.
Published in: Mol Pharmacol

Ligand: cirazoline (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 5.5 pKi
Reference (Journal): The selectivity of &#x3b1;-adrenoceptor agonists for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: cirazoline (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): The selectivity of &#x3b1;-adrenoceptor agonists for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: clonidine (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1974)
Primary target: no
Median affinity: 5.599999904632568 pKi
Reference (Journal): The selectivity of &#x3b1;-adrenoceptor agonists for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: clonidine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1974)
Median affinity: 6.9 pKi
Reference (Journal): Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes.
Published in: Mol Pharmacol

Ligand: clozapine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1989)
Median affinity: 7.7 pKi
Reference (Journal): Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
Published in: Jpn J Pharmacol

Ligand: corbadrine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1960), in combination with mepivacaine hydrochloride
Primary target: no
Median affinity: 5.599999904632568 pKi
Reference (Journal): Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes.
Published in: Mol Pharmacol

Ligand: (+)-cyclazosin (Synthetic organic)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: (+)-cyclazosin (Synthetic organic)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Synthesis and biological profile of the enantiomers of [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-cis-octahydroquinoxalin- 1-yl]furan-2-ylmethanone (cyclazosin), a potent competitive alpha 1B- adrenoceptor antagonist.
Published in: J Med Chem

Ligand: (+)-cyclazosin (Synthetic organic)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: no
Median affinity: 7.6 pKi
Reference (Journal): Synthesis and biological profile of the enantiomers of [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-cis-octahydroquinoxalin- 1-yl]furan-2-ylmethanone (cyclazosin), a potent competitive alpha 1B- adrenoceptor antagonist.
Published in: J Med Chem

Ligand: cyproheptadine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1961)
Median affinity: 6.9 pKi
Reference (Journal): Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
Published in: Jpn J Pharmacol

Ligand: dapiprazole (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1990)
Primary target: yes
Median affinity: 8.399999618530273 pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: dapiprazole (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1990)
Primary target: yes
Median affinity: 8.399999618530273 pKi
Reference (Webpage): National Toxicology Program: Dept of Health and Human Services.

Ligand: dibenamine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.400000095367432 pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: doxazosin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1990)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: doxazosin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1990)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Pharmacological characterization of A-131701, a novel R 1 -adrenoceptor antagonist selective for R 1A - and R 1D - compared to R 1B -adrenoceptors.
Published in: Drug Development Research

Ligand: HEAT (BE2254) (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.5 pKd
Reference (Journal): KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
Published in: Mol Pharmacol

Ligand: indanidine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 5.5 pKi
Reference (Journal): Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes.
Published in: Mol Pharmacol

Ligand: indoramin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: UK (1993)
Primary target: no
Median affinity:  pKi
Reference (Journal): Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification.
Published in: Br J Pharmacol

Ligand: indoramin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: UK (1993)
Primary target: no
Median affinity:  pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: ketanserin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Median affinity: 7.8 pKi
Reference (Journal): Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
Published in: Jpn J Pharmacol

Ligand: KMUP-1 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.690000057220459 pKi
Reference (Journal): cGMP-enhancing- and alpha1A/alpha1D-adrenoceptor blockade-derived inhibition of Rho-kinase by KMUP-1 provides optimal prostate relaxation and epithelial cell anti-proliferation efficacy.
Published in: Prostate

Ligand: labetalol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1984)
Primary target: yes
Median affinity:  pKi
Reference (Webpage): National Toxicology Program: Dept of Health and Human Services.

Ligand: labetalol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1984)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: methoxamine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Primary target: no
Median affinity:  pKi
Reference (Journal): KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
Published in: Mol Pharmacol

Ligand: methoxamine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Median affinity: 4.5 pKi
Reference (Journal): Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes.
Published in: Mol Pharmacol

Ligand: methoxamine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of &#x3b1;-adrenoceptor agonists for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: methoxamine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Primary target: no
Median affinity:  pEC50
Reference (Journal): The selectivity of &#x3b1;-adrenoceptor agonists for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: mianserin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Median affinity: 7.5 pKi
Reference (Journal): Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
Published in: Jpn J Pharmacol

Ligand: NAN 190 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9.2 pKi
Reference (Journal): Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
Published in: Jpn J Pharmacol

Ligand: (-)-noradrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1950)
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of &#x3b1;-adrenoceptor agonists for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: (-)-noradrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1950)
Median affinity: 6.3 pKi
Reference (Journal): Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes.
Published in: Mol Pharmacol

Ligand: (-)-noradrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1950)
Primary target: no
Median affinity:  pKi
Reference (Journal): KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
Published in: Mol Pharmacol

Ligand: (-)-noradrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1950)
Primary target: no
Median affinity:  pEC50
Reference (Journal): The selectivity of &#x3b1;-adrenoceptor agonists for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: (-)-noradrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1950)
Primary target: no
Median affinity:  pKi
Reference (Journal): Selectivity of the imidazoline alpha-adrenoceptor agonists (oxymetazoline and cirazoline) for human cloned alpha 1-adrenoceptor subtypes.
Published in: Br J Pharmacol

Ligand: NS-49 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Median affinity: 5.4 pKi
Reference (Journal): NS-49, a novel alpha 1a-adrenoceptor-selective agonist characterization using recombinant human alpha 1-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: olanzapine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: EMA & FDA (1996)
Primary target: no
Median affinity: 6.400000095367432 pA2
Reference (Journal): Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function.
Published in: Psychopharmacology (Berl.)

Ligand: oxymetazoline (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1986)
Primary target: no
Median affinity:  pKi
Reference (Journal): NS-49, a novel alpha 1a-adrenoceptor-selective agonist characterization using recombinant human alpha 1-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: oxymetazoline (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1986)
Primary target: no
Median affinity:  pEC50
Reference (Journal): The selectivity of &#x3b1;-adrenoceptor agonists for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: oxymetazoline (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1986)
Median affinity: 6.2 pKi
Reference (Journal): Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes.
Published in: Mol Pharmacol

Ligand: oxymetazoline (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1986)
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of &#x3b1;-adrenoceptor agonists for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: oxymetazoline (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1986)
Primary target: no
Median affinity:  pKi
Reference (Journal): KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
Published in: Mol Pharmacol

Ligand: phenoxybenzamine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1953)
Primary target: no
Median affinity: 8.399999618530273 pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: phentolamine (Synthetic organic)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: yes
Approval source: FDA (1952)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: phentolamine (Synthetic organic)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: yes
Approval source: FDA (1952)
Primary target: yes
Median affinity:  pKi
Reference (Journal): KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
Published in: Mol Pharmacol

Ligand: phenylephrine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1952)
Primary target: no
Median affinity: 4.699999809265137 pKi
Reference (Journal): The selectivity of &#x3b1;-adrenoceptor agonists for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: phenylephrine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1952)
Primary target: no
Median affinity:  pEC50
Reference (Journal): The selectivity of &#x3b1;-adrenoceptor agonists for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: phenylephrine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1952)
Primary target: no
Median affinity: 5.900000095367432 pKi
Reference (Journal): Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes.
Published in: Mol Pharmacol

Ligand: prazosin (Synthetic organic)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: yes
Approval source: FDA (1976)
Primary target: yes
Median affinity:  pKi
Reference (Journal): KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
Published in: Mol Pharmacol

Ligand: prazosin (Synthetic organic)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: yes
Approval source: FDA (1976)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification.
Published in: Br J Pharmacol

Ligand: prazosin (Synthetic organic)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: yes
Approval source: FDA (1976)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: prazosin (Synthetic organic)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: yes
Approval source: FDA (1976)
Primary target: yes
Median affinity:  pKi
Reference (Journal): In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists.
Published in: Br J Pharmacol

Ligand: risperidone (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1993), EMA (2022)
Median affinity: 7.4 pKi
Reference (Journal): Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
Published in: Jpn J Pharmacol

Ligand: ritanserin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.8 pKi
Reference (Journal): Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
Published in: Jpn J Pharmacol

Ligand: Ro-70-0004 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.2 pKi
Reference (Journal): In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists.
Published in: Br J Pharmacol

Ligand: RS-100329 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists.
Published in: Br J Pharmacol

Ligand: RS-100329 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: RS-17053 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification.
Published in: Br J Pharmacol

Ligand: RS-17053 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: RX18 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 10.25 pKi
Reference (Journal): High affinity ligands and potent antagonists for the &#x3b1;1D-adrenergic receptor. Novel 3,8-disubstituted [1]benzothieno[3,2-d]pyrimidine derivatives.
Published in: Eur J Med Chem

Ligand: RX18 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.149999618530273 pEC50
Reference (Journal): High affinity ligands and potent antagonists for the &#x3b1;1D-adrenergic receptor. Novel 3,8-disubstituted [1]benzothieno[3,2-d]pyrimidine derivatives.
Published in: Eur J Med Chem

Ligand: (S)-41 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.5 pKi
Reference (Journal): Identification of 3,4-dihydro-2H-thiochromene 1,1-dioxide derivatives with a phenoxyethylamine group as highly potent and selective &#x3b1;<sub>1D</sub> adrenoceptor antagonists.
Published in: Eur J Med Chem

Ligand: silodosin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (2008), EMA (2010)
Primary target: no
Median affinity:  pKi
Reference (Journal): KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
Published in: Mol Pharmacol

Ligand: silodosin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (2008), EMA (2010)
Primary target: no
Median affinity:  pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: SKF 105854 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.1 pKi
Reference (Journal): International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update.
Published in: Pharmacol Rev

Ligand: SKF 89748 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.1 pKi
Reference (Journal): Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes.
Published in: Mol Pharmacol

Ligand: SNAP5089 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.699999809265137 pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: S(+)-niguldipine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
Published in: Mol Pharmacol

Ligand: S(+)-niguldipine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification.
Published in: Br J Pharmacol

Ligand: S(+)-niguldipine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: spiperone (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.1 pKi
Reference (Journal): Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
Published in: Jpn J Pharmacol

Ligand: spiroxatrine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.900000095367432 pKi
Reference (Journal): Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
Published in: Jpn J Pharmacol

Ligand: spiroxatrine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.900000095367432 pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: St 587 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.5 pKi
Reference (Journal): Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes.
Published in: Mol Pharmacol

Ligand: [125I]HEAT (BE2254) (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues.
Published in: J Pharmacol Exp Ther

Ligand: [125I]HEAT (BE2254) (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
Published in: Mol Pharmacol

Ligand: [3H]prazosin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: tamsulosin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1997)
Primary target: yes
Median affinity:  pKi
Reference (Journal): KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
Published in: Mol Pharmacol

Ligand: tamsulosin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1997)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification.
Published in: Br J Pharmacol

Ligand: tamsulosin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1997)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: tamsulosin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1997)
Primary target: yes
Median affinity:  pKi
Reference (Journal): In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists.
Published in: Br J Pharmacol

Ligand: terazosin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1987)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: terazosin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1987)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist for the symptomatic treatment of benign prostatic hyperplasia.
Published in: J Med Chem

Ligand: upidosin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.8 pKi
Reference (Journal): Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification.
Published in: Br J Pharmacol

Ligand: WB 4101 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification.
Published in: Br J Pharmacol

Ligand: WB 4101 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
Published in: Mol Pharmacol

Ligand: WB 4101 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The affinity and selectivity of &#x3b1;-adrenoceptor antagonists, antidepressants, and antipsychotics for the human &#x3b1;1A, &#x3b1;1B, and &#x3b1;1D-adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: xylometazoline (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Primary target: no
Median affinity: 6 pKi
Reference (Journal): Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes.
Published in: Mol Pharmacol